SARS-CoV-2 Reduction

Jamie Balarashta - Study Director, Jeffery Trolingera - Principal Investigator
Aerosol Research and Engineering Laboratories, Kansas
Full Report


To evaluate the efficacy of the Defend 1050 at reducing aerosolized MS2 bacteriophage, a surrogate for SARS-CoV-2, the disease causing COVID-19.


MS2 bacteriophage was aerosolized into a 16m3, sealed environmental bioaerosol chamber containing the Defend 1050.

AGI impingers were used to sample the chamber bioaerosol concentrations. All impinger samples were serially diluted, plated and enumerated in triplicate to yield viable bioaerosol concentration at each sampling point and time. Samples were taken at 0, 15 and 30 minutes in order to quantify the reduction speed and capabilities of the Defend 1050.

Chamber control trial data was subtracted from the Defend 1050 trial data to yield net LOG reduction in the chamber for the bioaerosol challenges.

Summary of Results

The Defend 1050 was shown to reduce MS2 bacteriophage by 99.99% in 15 minutes.

The Defend 1050 showed a high net log reduction in a relatively short amount of time with average log reduction values ranging from 4.14 net Log in 15 minutes to 4.59 net log reduction in 30 minutes.

A net log reduction over 4.0 in 15 minutes indicates the speed and efficiency of this device against the MS2 bacteriophage.

Defend 1050 achieved 99.999% reduction of MS2, surrogate for SARS-CoV-2

Contact Us

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750